Company profilePharmaceutical#184 of 1,318 in Pakistan✓ No DRAP alerts

GRAY`S PHARMACEUTICALS

Pharmaceutical company · 97 brands · 102 molecules

Ranked #115 of 207 companies in Quinolone Antibacterials

97 registered products 33 pharmaceutical brands 102 distinct molecules 0 DRAP alerts

Company overview

97
registered products
33
pharmaceutical brands
102
distinct molecules
12
therapeutic classes
0
DRAP alerts

GRAY`S PHARMACEUTICALS is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 97 product registrations across 102 distinct molecules. It is the 184th largest registrant in Pakistan by product count, and ranks 115th of 207 in Quinolone Antibacterials. Its portfolio is concentrated in Quinolone Antibacterials and Antiepileptics. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by GRAY`S

4 products matched in our catalogue — each with its observed price and DRAP approved ceiling.

Antihistamines For Systemic Use 1

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

4
ceilings with an approval date
1
not revised in 2+ years
2024
oldest approval year
20241
20263
Longest without revision

Top molecules by brand count

Artemether6 brands
Lumefantrine4 brands
Paracetamol4 brands
Diclofenac3 brands
Loratadine2 brands
Paroxetine2 brands

Therapeutic classes

Quinolone Antibacterials · 2Antiepileptics · 2Macrolides, Lincosamides And Streptogramins · 2Antihistamines For Systemic Use · 1Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord) · 1Other Analgesics And Antipyretics · 1Antianemic, Iron Preparations · 1Other Beta-Lactam, Cephalosporins & Penems · 1Antibiotics For Topical Use · 1Antidiarrheals, Intestinal Antiinflammatory/Antiinfective · 1Calcium Channel Blockers · 1Anti-Infective, Ophthalmologicals · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official1 products · Rs 122.84 – Rs 122.84
Median across source: Rs 122.84

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

VALOR PHARMACEUTICALS46 shared molecules
GLOBAL BRANDS DISTRIBUTORS41 shared molecules
NEUTRO PHARMA (PVT) LTD.38 shared molecules
SEARLE PAKISTAN (PVT.) LTD.36 shared molecules
BIO LABS (PVT) LTD.35 shared molecules
SHROOQ PHARMACEUTICALS35 shared molecules

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

VALOR PHARMACEUTICALS holds 159 molecules not in this portfolio
000 I.UAcetylcysteineAcitretinAcyclovirAdapaleneAdaplene
GLOBAL BRANDS DISTRIBUTORS holds 5 molecules not in this portfolio
CeftriaxoneDiloxanideEsomeprazoleLignocaineMetronidazole
Wilshire Laboratories (Private) Limited holds 130 molecules not in this portfolio
AcyclovirAcyclovir SodiumAlfacalcidolAmlodipineAmoxicillinAmoxycillin

Get the full profile for GRAY`S

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.